Overview

Pharmacokinetic Study of DARE-BV1

Status:
Completed

Trial end date:
2020-12-02

Target enrollment:

Participant gender:

Summary

Single-Center, Phase 1, Single-dose PK study of DARE-BV1 (2% clindamycin phosphate vaginal gel, 100mg) under development for the treatment of bacterial vaginosis (BV).

Phase:

Phase 1

Details

Lead Sponsor:

Daré Bioscience, Inc.